Filing summary
Company: Jade Biosciences, Inc. (Nasdaq: JBIO). Filing: Form 8-K, Item 8.01, reporting an event announced September 30, 2026. The filing reports preclinical findings for JADE301, an investigational anti-IFN-β antibody being developed for dermatomyositis (DM).
Financial and operating metrics
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It does not provide financial guidance.
Preclinical findings and development plans
- JADE301 is a fully human IgG1 monoclonal antibody with a YTE modification, designed to neutralize IFN-β. The filing reports a binding KD of 11.3 pM, approximately 2.5 times the affinity of the dazukibart comparator, and no detectable binding to other interferon family proteins.
- In preclinical assays, it inhibited pSTAT induction with an IC50 of 13 pM, approximately 2.5 times more potent than the comparator. In human dermal fibroblasts, it inhibited MX-1 induction with an IC50 of 11 pM, approximately eight times more potent than the comparator.
- In non-human primates (NHPs), the reported half-life was approximately 30 days after intravenous dosing and 25 days after subcutaneous dosing. Translational modeling estimated human subcutaneous bioavailability of 73%–75%; these are preclinical and modeled results, not clinical findings.
- Muscle concentrations in NHPs were approximately 1%–4% of serum concentrations. In a GLP NHP toxicology study, subcutaneous doses up to 200 mg/kg every two weeks were reported as well tolerated, with no treatment-related adverse clinical observations or meaningful laboratory, other standard safety, or histopathology findings.
- Jade expects to begin a placebo-controlled, single-ascending-dose Phase 1 study in 24 healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027. The study is intended to assess safety, tolerability, pharmacokinetics, and immunogenicity.
Changes, outlook, and risks
The filing announces JADE301 preclinical results; it does not report a prior-period financial comparison. Jade cites the findings as supporting the potential for infrequent subcutaneous dosing, but therapeutic benefit, clinical safety, human exposure, and dosing have not been established. The planned trial and interim-data timing are forward-looking expectations.
Risks highlighted include trial delays or failure to show desirable efficacy or predicted performance, adverse events or safety signals, differences between modeled and observed results, development costs or delays, enrollment and regulatory challenges, and reliance on third-party development, manufacturing, and supply vendors. The filing refers investors to Jade’s other SEC filings, including its Form 10-Q for the quarter ended June 30, 2026.
Important facts for investors to verify
- Whether the Phase 1 trial begins on the expected schedule and whether interim data are reported in the second half of 2027.
- Human safety, tolerability, pharmacokinetics, immunogenicity, and subcutaneous bioavailability; the reported bioavailability estimate is based on modeling.
- Whether preclinical potency and NHP findings translate to patients with DM, and whether clinical studies establish efficacy and a practical dosing interval.
- Financial position, cash runway, and funding needs in Jade’s financial filings; this 8-K does not provide those figures.